LOL you people are funny, defending these stocks like they are your mother
Its very simple: buy BOTH of them, TSRX and DRTX. Why not make money on both?
If we are comparing drug vs drug, TSRX wins hands down. BUT, if we are comparing monetary gain from owning these stocks, its pretty even right now.
1. Dalabavcin was compared to vancomycin/linezolid in phase3 studies
2. Tedizolud was just compared to linezolid. BIG difference.
3. Tsrx market cap is 550 million vs drtx 220 million. Drtx goes to 16 market cap is 440. If tsrx goes to 22 it's 1 billion market cap. Significantly more money to be made here. Company owned bt private equity who has done this before and sold company.